ESMO 2025: AI biomarkers move from promise to practice

At this year’s ESMO Congress in Berlin, one message was clear: AI-based biomarkers are exiting the lab and entering real clinical decisions. From digital pathology to CT radiomics and multi-omics, teams showed practical ways to read response earlier and adapt treatment more precisely.






Blog source Url:- https://nexomic.com/blog/esmo-....2025-ai-biomarkers-m

Tumor-agnostic Biomarkers | Nexomic Limited



Tumor-agnostic biomarkers discovered by Nexomic Limited provide universal targets for cancer therapies regardless of tumor origin, enabling broader treatment applications and improved patient outcomes across multiple cancer types.



https://nexomic.com/

ESMO 2025: AI biomarkers move from promise to practice

At this year’s ESMO Congress in Berlin, one message was clear: AI-based biomarkers are exiting the lab and entering real clinical decisions. From digital pathology to CT radiomics and multi-omics, teams showed practical ways to read response earlier and adapt treatment more precisely.



https://nexomic.com/blog/esmo-....2025-ai-biomarkers-m

ESMO 2025: AI biomarkers move from promise to practice

At this year’s ESMO Congress in Berlin, one message was clear: AI-based biomarkers are exiting the lab and entering real clinical decisions. From digital pathology to CT radiomics and multi-omics, teams showed practical ways to read response earlier and adapt treatment more precisely.



https://nexomic.com/blog/esmo-....2025-ai-biomarkers-m

Ai Multi-omics Biomarker Discovery | Nexomic Limited



AI Multi-omics biomarker discovery at Nexomic Limited leverages advanced computational and biological approaches to identify critical biomarkers across multiple omics layers, enabling precision medicine and transformative healthcare solutions.



https://nexomic.com/